← Back to patent-cliff list
Clesacostat
Tier C — Watch / tradeClesacostat
Pfizer Inc.
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Acetyl-CoA carboxylase
Indications (approved)：Non-alcoholic steatohepatitis, Liver cirrhosis, Hepatic function decline
Regional status
US
Phase II
2017-08-22
EU
Phase II
2017-08-22
China
Phase II
2020-06-15
Japan
Phase II
2020-06-15
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Clesacostat?
Approved indications include: Non-alcoholic steatohepatitis, Liver cirrhosis, Hepatic function decline.
When does the Clesacostat patent expire?
No public expiry year is available for Clesacostat yet; this page updates once verified.
How do I get a quote for Clesacostat intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-09